July 12th 2024
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 17 - 18, 2025
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Rescuing an Essential Component of Psychiatry: Psychotherapy Training in Psychiatric Education
February 10th 2020A diminished interest in psychotherapeutic interventions runs the risk of missing patients' emotional, social, and practical needs (including medication-modifiable symptoms) and, thus, less clinically responsible care.
Read More
Integrating Psychotherapy and Psychopharmacology in the Treatment of Major Depressive Disorder
January 30th 2020Although multiple interventions exist for major depressive disorder (MDD), only partial response is achieved in many patients and recurrence is common. Combining medication and psychotherapy may enable more effective treatment of MDD.
Read More
Year in Review: 2019 Special Reports in Psychiatry
December 2nd 2019As varied as the field of psychiatry itself, our Special Report collections covered issues such as eating disorders, traumatic brain injury, practice management, schizophrenia and depression, complex medical comorbidities, and more. Here's a sampling.
Read More
Multidisciplinary Team Explores Link Between Asthma and Depression
August 16th 2019In a first-of-its-kind study, researchers from the Icahn School of Medicine at Mount Sinai, Montefiore Health System, and Albert Einstein College of Medicine are working together to examine the link between depression and asthma in older adults.
Read More